UK, US Regulators Launch New Collaboration Programme

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. Food and Drug Administration (FDA) have announced a new liaison programme aimed at strengthening regulatory cooperation and accelerating innovation in healthcare, marking a significant milestone in transatlantic regulatory relations.

The initiative was unveiled during the DIA Global Annual Meeting in Philadelphia by MHRA Chief Executive Lawrence Tallon and FDA Deputy Commissioner Grace Graham. The programme will introduce dedicated liaison officers within both agencies, creating formal channels for ongoing collaboration and information exchange.

The new roles are designed to enhance day-to-day cooperation, facilitate scientific dialogue, and improve coordination on emerging regulatory issues. Officials said the programme will help both agencies respond more effectively to rapid advances in healthcare technologies, including innovative medicines, medical devices, biologics, and artificial intelligence-driven healthcare solutions.

The announcement builds on a long-standing relationship between the two regulators and formalizes efforts to deepen cooperation while preserving each agency’s regulatory independence. Both organizations emphasized that they will continue to make their own regulatory decisions, even as they work toward greater alignment in regulatory science and policy.

According to Tallon, the initiative represents an important step toward reducing barriers for companies seeking to bring products to market in both countries. He noted that closer collaboration will improve the sharing of expertise and help align approaches to evaluating emerging technologies and medical innovations.

Industry stakeholders have welcomed the move, highlighting its potential to streamline product development and regulatory approval processes. Greater alignment between the MHRA and FDA could help reduce duplication, improve predictability for developers, and speed patient access to new therapies and medical technologies.

Grace Graham said the programme will strengthen institutional knowledge within both organizations and enhance global oversight of drugs, biologics, and medical devices. She added that collaboration on regulatory science can help shorten development timelines and support more efficient pathways for bringing medical products to patients.

The initiative follows commitments made earlier this year to expand cooperation between the UK and the United States on medical device regulation. The liaison programme is expected to support broader pharmaceutical and healthcare partnerships between the two nations while fostering closer engagement among scientific, technical, and policy teams.

Healthcare and life sciences organizations on both sides of the Atlantic praised the announcement. Representatives from industry groups including the Association of British HealthTech Industries (ABHI), AdvaMed, and BritishAmerican Business said stronger regulatory cooperation could reduce costs, simplify market access, encourage investment, and improve patient access to life-saving technologies.

Peter Ellingworth, Chief Executive of ABHI, described the development as a positive step toward a more connected regulatory environment that could make the UK a more attractive destination for innovation and investment. Meanwhile, AdvaMed President and CEO Scott Whitaker said the collaboration demonstrates the type of forward-looking regulatory leadership needed to keep pace with the rapid evolution of medical technology.

The programme also aligns with the MHRA’s broader strategy of strengthening international partnerships and contributing to the development of global regulatory standards. As healthcare technologies continue to evolve, officials from both agencies said the collaboration will help ensure high standards of safety and effectiveness while supporting innovation and improving patient outcomes worldwide.

With increasing globalization of healthcare research and product development, the new liaison programme signals a shared commitment by the UK and U.S. regulators to work more closely together in addressing future public health challenges and advancing medical innovation.